Lung Cancer Clinical Trial
Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer
Summary
The purpose of this study was to evaluate the efficacy and safety of the combination of nivolumab plus epacadostat in combination with platinum chemotherapy compared with platinum chemotherapy alone, in participants with treatment-naïve Stage 4 or recurrent non-small cell lung cancer (NSCLC).
Eligibility Criteria
Inclusion Criteria:
Histologically confirmed stage IV or recurrent NSCLC of squamous or non-squamous histology that is not amenable to therapy with curative intent (surgery or radiation therapy with or without chemotherapy).
No prior treatment with systemic anti-cancer therapy for Stage IV disease.
Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to1.
Measurable disease by computed tomography or magnetic resonance imaging per RECIST v1.1.
Documentation of program death ligand-1 (PD-L1) status of 0 to 49% by IHC performed by the central laboratory prior to randomization.
Other protocol inclusion criteria may apply
Exclusion Criteria:
Known epidermal growth factor receptor (EGFR) mutations sensitive to available targeted inhibitor therapy.
Known ALK or ROS1 rearrangements sensitive to available targeted inhibitor therapy.
Untreated central nervous system (CNS) metastases.
Unevaluable PD-L1 status or PD-L1 status of ≥ 50% by IHC performed by a central laboratory.
Carcinomatous meningitis.
Active, known or suspected autoimmune disease.
Prior treatment with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, IDO1 targeted agent, or any other antibody or drug targeting T cell co-stimulation or checkpoint pathways.
History of allergy or hypersensitivity to platinum-containing compounds or study drug components.
Physical and laboratory test findings outside the protocol-defined range.
Other protocol exclusion criteria may apply.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 2 Locations for this study
Anaheim California, 92801, United States
Wichita Kansas, 67214, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.